-
Eli Lilly Full Year 2025 Financial Report
Eli Lilly
Eli Lilly's 2025 results show a 45% revenue increase to $65.2B, driven by Mounjaro and Zepbound sales. With strong growth in profits and an optimistic 2026 outlook, the company continues to lead in metabolic diseases and oncology treatments.
-
Eli Lilly 2025 H1 Report
Financial statements
Eli Lilly's 2025 H1 revenue surged 41% to $28.29B, driven by tirzepatide sales hitting $14.7B. Mounjaro and Zepbound shine as blockbuster drugs, boosting Lilly's global pharmaceutical ranking.
-
-
-
-
Pharma's $158B U.S. Manufacturing Surge
Market Trend
Major pharmaceutical companies pledge $158 billion to U.S. manufacturing to sidestep tariff threats, funding facilities from California to North Carolina. Lilly, J&J, Novartis, Roche and Regeneron drive billions in reshoring investments, creating thousands of jobs.
-
Stylus Medicine Raises $85 Million!
Eli Lilly
Stylus Medicine raises $85M to develop in vivo CAR-T cell therapies, targeting gene insertion, non-viral DNA delivery, and cell therapy solutions with backing from Eli Lilly, Johnson & Johnson, and others.
-
-
Eli Lilly's Q1 2025 Financial report
Market Trend
Eli Lilly's Q1 2025 revenue surged 45% to $12.73B, driven by Mounjaro and Zepbound. U.S. GLP-1 prescription share hit 53.3%, surpassing Novo Nordisk. Key R&D and regulatory milestones achieved.
-
永定县|
芦溪县|
江油市|
石门县|
陵川县|
日喀则市|
谷城县|
朝阳县|
呈贡县|
弋阳县|
阿克|
博爱县|
镇宁|
于都县|
山丹县|
绥棱县|
宁明县|
南投市|
利津县|
西昌市|
社会|
余姚市|
乐至县|
客服|
吉首市|
临沧市|
滦南县|
绥滨县|
安陆市|
广州市|
林周县|
商洛市|
任丘市|
万荣县|
邳州市|
漳浦县|
新宁县|
陆川县|
乐昌市|
田东县|
翁源县|